<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429076</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000566</org_study_id>
    <nct_id>NCT02429076</nct_id>
  </id_info>
  <brief_title>EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia</brief_title>
  <official_title>Electroencephalogram Studies of Intravenous Methylphenidate-Induced Emergence From General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the hypothesis that methylphenidate actively induces&#xD;
      emergence from propofol and sevoflurane general anesthesia in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basic science and clinical data suggest that activation of one or more of the brain's arousal&#xD;
      pathways is a highly plausible way to induce active emergence from general anesthesia. The&#xD;
      investigators have compelling experimental data demonstrating that methylphenidate is highly&#xD;
      effective in actively inducing emergence from isoflurane and propofol general anesthesia in&#xD;
      rodents. The available literature suggests that IV methylphenidate would be safe to&#xD;
      administer to patients recovering from general anesthesia, and that in addition to promoting&#xD;
      arousal, it would enhance breathing. Both of these effects would be highly desirable in&#xD;
      patients recovering from general anesthesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We are not going to complete this study with healthy volunteers at this time.&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to methlyphenidate administration</measure>
    <time_frame>minutes to response, expected average is less than 10 minutes</time_frame>
    <description>The number of minutes from the administration of methylphenidate until subjects respond to verbal commands</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Active Emergence From General Anesthesia</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive propofol general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive sevoflurane general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV methylphenidate</intervention_name>
    <description>IV methylphenidate will be administered to induce emergence from general anesthesia.</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhaled anesthetic</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>IV anesthetic</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-36 years&#xD;
&#xD;
          2. ASA classification 1 or 2&#xD;
&#xD;
          3. Normal body weight, BMI â‰¤ 30&#xD;
&#xD;
          4. Non-smoker&#xD;
&#xD;
          5. Right handed&#xD;
&#xD;
          6. No history of taking stimulants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In general, patients will be excluded from the study if the state of their chronic&#xD;
             health problems gives them an ASA physical status classification of 3 or beyond.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ken Solt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

